Olanzapine reduces physical activity in rats exposed to activity-based anorexia: Possible implications for treatment of anorexia nervosa?

被引:65
作者
Hillebrand, JJG
van Elburg, AA
Kas, MJH
van Engeland, H
Adan, RAH
机构
[1] Univ Utrecht, Med Ctr, Dept Pharmacol & Anat, Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Dept Child & Adolescent Psychiat, Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands
[3] Altrecht Rintveld Eating Disorders, Zeist, Netherlands
关键词
hyperactivity; anorexia; antipsychotic; food restriction; running wheel;
D O I
10.1016/j.biopsych.2005.04.008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Anorexia nervosa (AN) patients often show extreme hypophagia and excessive physical activity. Activity-based anorexia (ABA) is considered an animal model of AN and mimics. food restriction and hyperactivity in rats. This study investigated whether treatment with olanzapine (Zyprexa) reduces the development of ABA in rats. The effect of olanzapine treatment in AN patients was also evaluated in a small open-label study. Methods: Rats were chronically (1 week) infused with olanzapine (75 mg/kg) and exposed to the ABA model or ad libitum feeding. Hyperactive AN patients were followed for up to 3 months of olanzapine treatment (5 mg/kg). Results: Olanzapine treatment reduced development of ABA in rats by reducing running wheel activity, starvation-induced hypothermia and activation of the hypothalamus-pituitary-adrenal axis. Olanzapine treatment reduced activity levels of AN patients compared with untreated AN Patients, without affecting body weight and plasma leptin levels. Conclusions: Olanzapine treatment reduced wheel running and thereby diminished development of ABA in rats. Olanzapine treatment also reduced physical activity in hyperactive AN patients in a small open-label study. These data support the need for controlled studies investigating the pulative beneficial of effects of olanzapine treatment in ANP patients.
引用
收藏
页码:651 / 657
页数:7
相关论文
共 56 条
[52]   PIMOZIDE COMBINED WITH BEHAVIOR-THERAPY IN THE SHORT-TERM TREATMENT OF ANOREXIA-NERVOSA - A DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER STUDY [J].
VANDEREYCKEN, W ;
PIERLOOT, R .
ACTA PSYCHIATRICA SCANDINAVICA, 1982, 66 (06) :445-450
[53]   Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice [J].
Vickers, SP ;
Clifton, PG ;
Dourish, CT ;
Tecott, LH .
PSYCHOPHARMACOLOGY, 1999, 143 (03) :309-314
[54]   Comparative effects of continuous infusion of mCPP, Ro 60-0175 and d-fenfluramine on food intake, water intake, body weight and locomotor activity in rats [J].
Vickers, SP ;
Benwell, KR ;
Porter, RH ;
Bickerdike, MJ ;
Kennett, GA ;
Dourish, CT .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (06) :1305-1314
[55]   Eating disorders: Progress and problems [J].
Walsh, BT ;
Devlin, MJ .
SCIENCE, 1998, 280 (5368) :1387-1390
[56]   Association between a polymorphism of the 5-HT2C receptor and weight loss in teenage girls [J].
Westberg, L ;
Bah, J ;
Råstam, M ;
Gillberg, C ;
Wentz, E ;
Melke, J ;
Hellstrand, M ;
Eriksson, E .
NEUROPSYCHOPHARMACOLOGY, 2002, 26 (06) :789-793